Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$19.98 USD

19.98
1,470,373

-0.28 (-1.38%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $19.97 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 541 - 560 ( 722 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 541

01/11/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 12

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 542

01/09/2015

Company Report

Pages: 7

Preannounced Q4 Suggests to Us That Demand Not Materially Impacted by Warning Letter; Reiterate

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 543

01/05/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 5

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 544

01/02/2015

Industry Report

Pages: 46

January and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 545

12/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 546

12/24/2014

Company Report

Pages: 7

Symphony Health EXPAREL Estimates for November on Track for Q4; Reiterate OUTPERFORM and $119 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 547

12/19/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 548

12/14/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 549

12/03/2014

Industry Report

Pages: 45

December and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 550

11/19/2014

Daily Note

Pages: 7

Symphony Health EXPAREL Estimates for October On-Track for Q4; Reiterate OUTPERFORM and $119

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 551

11/19/2014

Daily Note

Pages: 7

Symphony Health EXPAREL Estimates for October On-Track for Q4; Reiterate OUTPERFORM and $119

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 552

11/04/2014

Daily Note

Pages: 46

November and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 553

11/03/2014

Company Report

Pages: 6

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 554

11/02/2014

Company Report

Pages: 9

We Believe Increasing EXPAREL Demand Prompted Increasing Manufacturing Capacity; Reiterate

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 555

10/28/2014

Daily Note

Pages: 6

Use of EXPAREL Reduces Opioid Related Adverse Events; Reiterate OUTPERFORM and $117 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 556

10/24/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 27

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 557

10/22/2014

Daily Note

Pages: 7

Q3 Preview: Symphony Health Estimate Suggests Strong Q3 EXPAREL Sales; Reiterate OUTPERFORM and $117 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 558

10/21/2014

Daily Note

Pages: 7

Q3 Preview: Symphony Health Estimate Suggests Strong Q3 EXPAREL Sales; Reiterate OUTPERFORM and $117 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 559

10/17/2014

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 560

10/13/2014

Daily Note

Pages: 6

EXPAREL Safety Profile Supports Use in Peripheral Nerve Block

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party